Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 907 of 6351
-
New combo tackles lung cancer after immunotherapy fails
Disease control OngoingImmune checkpoint inhibitor (ICI)-based regimen has been widely used in first-line treatment of driver-gene-negative non-squamous non-small cell lung cancer. This study investigate the efficacy and safety of the combination of bevacizumab plus nab-paclitaxel and platinum as secon…
Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New ALK inhibitor NVL-655 enters trials for Hard-to-Treat cancers
Disease control Recruiting nowPhase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors.…
Phase 1/2 • Sponsor: Nuvalent Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New shot could tame blistering skin disease and cut steroid use
Disease control CompletedARGX-113-2009 is an operationally seamless 2-part, phase 2/3, prospective, global, multicenter, randomized, double-blinded, placebo-controlled study to investigate the efficacy, safety, tolerability, immunogenicity, participant-reported outcome measures (including those assessing…
Phase 2/3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Custom-Made vaccine trains immune system to fight advanced cancers
Disease control Recruiting nowThis phase I trial studies the safety of personalized neo-antigen peptide vaccine in treating patients with stage IIIC-IV melanoma, hormone receptor positive HER2 negative breast cancer that has spread from where it first started (primary site) to other places in the body (metast…
Phase 1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Could a simple home program level the playing field for kids in poverty?
Prevention OngoingStructural inequities and historical underinvestment in marginalized communities create developmental contexts that constrain access to high-quality education, healthcare, stable housing, and other critical resources. This study evaluates effects of a strengths-based, community-l…
Sponsor: University of Pennsylvania • Aim: Prevention
Last updated Aug 09, 2026 00:00 UTC
-
Could a Telomere-Targeting drug revive immunotherapy in lung cancer?
Disease control OngoingTHIO is a first-in-class small molecule telomere targeting agent, in development for the treatment of non-small cell lung cancer (NSCLC) in combination with cemiplimab (LIBTAYO®). THIO is preferentially incorporated into telomeres sequence in telomerase-positive cells leading to …
Phase 2 • Sponsor: Maia Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Ovarian graft could spare young cancer patients from early menopause
Disease control OngoingPelvic chemoradiotherapy (CRT) is an effective treatment for Locally Advanced Cervical Cancer (LACC). However, CRT induces premature ovarian failure ceasing the production of ovarian hormones. This may lead to severe consequences to the patient's life quality, sexuality and overa…
Phase 1/2 • Sponsor: MARILIA ALBANEZI BERTOLAZZI • Aim: Disease control
Last updated Jun 26, 2026 14:04 UTC
-
New hope for Hard-to-Treat cancers: GAIA-102 trial targets malignant ascites
Disease control Recruiting nowPhase I Part : Confirm the safety of GAIA-102 as a monotherapy or GAIA-102 and pembrolizumab in combination for advanced gastrointestinal cancer of microsatellite stable with malignant ascites, and determine the recommended number of doses for Phase II part. Phase II Part : Re…
Phase 1/2 • Sponsor: Kyushu University • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New combo therapy shows promise for hard-to-treat throat cancer
Disease control OngoingThe study is to evaluate the efficacy of KL-A167 combined with cisplatin and gemcitabine vs placebo combined with cisplatin and gemcitabine in the treatment of recurrent or metastatic nasopharyngeal carcinoma, as measured by progression-free survival (PFS) per the Response Evalua…
Phase 3 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Can a lung fibrosis drug help miners breathe easier?
Disease control Recruiting nowThis study is a randomized, double-blind, placebo-controlled, multicenter clinical study. The main purpose of this study was to confirm the efficacy and safety of pirfenidone capsules in the treatment of pneumoconiosis.
Phase 3 • Sponsor: Beijing Continent Pharmaceutical Co, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Family navigator may shorten the wait for youth mental health care
Disease control CompletedThis study will focus on developing and testing a family-based mental health navigator intervention, the Family Mental Health Navigator (FMHN), to evaluate whether the intervention combined with mHealth is preliminary efficacious in improving mental health service initiation and …
Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a daily pill help kids with rare blood disorder?
Disease control OngoingStudy ACTIVATE-Kids (AG348-C-023) will evaluate the efficacy and safety of orally administered mitapivat as compared with placebo in pediatric participants with pyruvate kinase deficiency (PKD) who are not regularly receiving blood transfusions. Participants will be randomized 2:…
Phase 3 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can 'Zombie Cell' cleaners help frail cancer survivors walk faster?
Symptom relief OngoingThis is a first-in survivor pilot study with the goal of establishing preliminary evidence of efficacy, safety, and tolerability of two senolytic regimens to reduce markers of cellular senescence (primary outcome: p16\^INK4a) and improve frailty (primary outcome: walking speed) i…
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
New hope for colorectal cancer: drug duo aims to wipe out hidden tumor DNA
Disease control Recruiting nowTo measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving TAS-102 therapy. ctDNA is genetic material from tumor cells that can be found and measured in the blood.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Could less radiation be just as good for HPV throat cancer?
Disease control OngoingThis phase II trial tests whether reduced dose radiation therapy after transoral robotic surgery works in treating patients with human papillomavirus (HPV)-positive oropharyngeal cancer. HPV positive oropharyngeal cancer has a better prognosis than oropharyngeal cancer not caused…
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Tiny electric needles: a new weapon against chronic neck pain?
Symptom relief CompletedThis prospective trial will be a single-center, participant-blinded, randomized controlled trial. It is reported in previous studies that both acupuncture and transcutaneous electrical nerve stimulation are effective in reducing neck pain comparing to placebo or exercise. Taking …
Sponsor: Shi Hangyu • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Experimental drug shows promise for Tough-to-Treat prostate cancer
Disease control OngoingThis is an open-label, phase II umbrella trial assessing the anti-tumor activity of enfortumab alone and in combination with other anti-cancer agents in subjects with metastatic castration-resistant prostate cancer. The trial will open to enrollment in Cohort A, enfortumab monoth…
Phase 2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Two-Drug maintenance strategy aims to stall advanced bladder cancer
Disease control OngoingThis phase III trial compares the effect of adding cabozantinib to avelumab versus avelumab alone in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Cabozantinib may stop the growth of t…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New Needle-Free treatment could replace surgery for adrenal tumors
Disease control Recruiting nowIn this study, the investigators will perform endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) treatment of left-sided adrenal tumours in patients with primary aldosteronism (PA) and in patients with mild autonomous cortisol secretion (MACS). Four different study gr…
Sponsor: Haukeland University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New combo targets Gene-Mutated breast cancer after first treatment fails
Disease control OngoingThe study is a nationwide, multicenter single-arm phase 2 study. The current phase 2 study investigates the efficacy of the combination of fulvestrant and alpelisib directly after progression on fulvestrant (either in first or second line, with or without previous use of CDK4/6-i…
Phase 2 • Sponsor: Borstkanker Onderzoek Groep • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC